Merck & Co Inc

NYSE:MRK

106.39

+0.47 (+0.44%)

7:59:55 PM EDT: $106.54 +0.15 (+0.14%)

Products

FDA Approves Merck’S Keytruda® As Adjuvant Therapy For Certain Patients With Renal Cell Carcinoma (Rcc) Following Surgery

Published: 11/18/2021 11:57 GMT

Merck & Co Inc (MRK) - FDA Approves Merck’s Keytruda® (pembrolizumab) As Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (rcc) Following Surgery.
Merck -approval Based on Data From Phase 3 Keynote-564 Trial, in Which Keytruda Showed Statistically Significant Improvement in Disease-free Survival.